General

Peng Li   Doctoral supervisor  Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
Email: li_peng@gibh.ac.cn
Telephone: 18026219834
Address: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences. 190 Kaiyuan Avenue, Science Park, Guangzhou, China.
Postcode:  510530

Research Areas

Tumor Immunotherapy;  Humanized Mice; The Mechanism of Tumor Initiation and Matastasis.

Education

Experience

   
Work Experience

2011/9 up to now, Guangzhou Institutes of Biomedicine and Health, CAS (Guangzhou, China), Principal Investigator

2010/10-2011/8, Welcome Trust Sanger Institute (Cambridge, UK), Postdoctor


Honors & Distinctions

2020,Second Prize of Science and Technology Progress of Guangdong Province

2017,China Patent Excellence Award

2017,Patent Excellence Award of Guangdong Province

2017, LEADERS INTERNATIONAL LEADER FELLOWSHIP between THE RORAL SOCIETY OF NEW ZEALAND AND MALAGHAN INSTITUTE OF MEDICAL RESEARCH AND PROFESSOR PENG LI

2015, NSFC(Natural Science Foundation of China)- Excellent Youth Fund

2014, Guangdong Natural Science Foundation- Outstanding Youth Fund

2014, Guangdong Technical Innovation Outstanding Young Scholar

Publications

   
Papers

  1. Qin L, Cui Y, Yuan T, Chen D, Zhao R, Li S, Jiang Z, Wu Q, Long Y, Wang S, Tang Z, Pan H, Li X, Wei W, Yang J, Luo X, Zhang Z, Tang Q, Liu P, Weinkove R, Yao Y, Qin D, Thiery JP*, Li P*. Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis. Nat Commun. 2022 Oct 13;13(1):6051.
  2. Jiang Z#, Cheng L#, Wu Z, Zhou L, Hong Q, Wu Q, Long Y, Huang Y, Xu G, Yao Y, Tang C, Zhang Z, Yang L, Luo W, Yang J, Gong L, Liu P, Chen X, Cui S, Zhang Q, Li Y*, Li P*. Transforming primary human hepatocytes into hepatocellular carcinoma with genetically defined factors. EMBO Rep. 2022 Jun 7;23(6):e54275.
  3. Li S#, Zhao R#, Zheng D, Qin L, Cui Y, Li Y, Jiang Z, Zhong M, Shi J, Li M, Wang X, Tang Z, Wu Q, Long Y, Hu D, Wang S, Yao Y, Liu S, Yang LH, Zhang Z, Tang Q, Liu P, Li Y*, Li P*. DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2D. Mol Ther Oncolytics. 2022 Jun 6;26:15-26.
  4. Zheng D#, Wang X#, Cheng L, Qin L, Jiang Z, Zhao R, Li Y, Shi J, Wu Q, Long Y, Wang S, Tang Z, Wei W, Yang J, Li Y, Zhou H, Liu Q, Liu P, Chen X, Yao Y, Yang L, Li P*. The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies. Front Immunol. 2022 May 26;13:808347.
  5. Jiang Z#, Qin L#, Tang Y#, Liao R, Shi J, He B, Li S, Zheng D, Cui Y, Wu Q, Long Y, Yao Y, Wei Z, Hong Q, Wu Y, Mai Y, Gou S, Li X, Weinkove R, Norton S, Luo W, Feng W, Zhou H, Liu Q, Chen J, Lai L, Chen X, Pei D, Graf T, Liu X, Li Y, Liu P*, Zhang Z*, Li P*. Human induced-T-to-natural killer cells have potent anti-tumour activities. Biomark Res. 2022 Mar 24;10(1):13.
  6.  Pang Z#. Shi J#, Qin L#, Chen A#, Tang Y, Yang H, Huang Y, Wu Q, Li X, He B, Li T, Liang B, Zhang J, Gao B, Liu M, Feng Y, Ye X, Chen X, Wang L, Yu Tian1, Hao Li1, Li J, Hu H, He J, Hu Y, Zhi C, Tang Z, Gong Y, Xu F, Xu L, Fan W, Zhao M, Chen D, Lian H*, Yang L*, Li P*, Zhang Z*. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. J Hematol Oncol. 2021 Jul 29;14(1):118.
  7.  Zhao, R#., Cui, Y#., Zheng, Y., Li, S., Lv, J., Wu, Q., Long, Y., Wang, S., Yao, Y., Wei, W., Yang, J., Wang, B. C., Zhang, Z., Zeng, H., Li, Y*., & Li, P*. Human Hyaluronidase PH20 Potentiates the Antitumor Activities of Mesothelin-Specific CAR-T Cells Against Gastric Cancer, Front Immunol. 2021 Jul 13;12:660488.
  8. Jiang Z#, Liao R#, Lv J#, Li S, Zheng D, Qin L, Wu D, Chen S, Long Y, Wu Q, Wang S, Lin S, Huang X, Tang Z, Shi P, Zhou H, Liu Q, Zhao R, Li Y, Jie Y, Wei W, Lai P, Du X, Cui S, Weinkove R, Liu P, Pei D, Yao Y*, Li P*. IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells. Leukemia. 2021 May;35(5):1380-1391.
  9. Lai P#, Chen X#, Qin L#, Jiang Z, Luo C, Huang X, Wu S, Ling W, Wang Y, Wang J, Deng C, Huang L, Zeng L, Lu Z, Zhong L, Liao P, Li M, Chen D, Geng S, Wu P, Tang Z, Pei D, Du X*, Li P*, Weng J*. The efficacy and safety of CAR-T cell therapy in patients with refractory ALL and concomitant HBV infection. Leukemia. 2020 Oct;34(10):2790-2793. Epub 2020 Jul 6.
  10.  Qin L, Zhao R, Chen D, Wei X, Wu Q, Long Y, Jiang Z, Li Y, Wu H, Zhang X, Wu Y, Cui S, Wei W, Yao H, Liu Z, Cao S, Yao Y*, Zhang Z*, Li P*. Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth. Biomark Res. 2020 Jun 3;8:19.
  11. Wu D, Lv J, Zhao R, Wu Z, Zheng D, Shi J, Lin S, Wang S, Wu Q, Long Y, Li P*, Yao Y*. PSCA is a target of chimeric antigen receptor T cells in gastric cancer. Biomark Res. 2020 Jan 28;8:3.
  12.   Lv J#, Zhao R#, Wu D#, Zheng D, Wu Z, Shi J, Wei X, Wu Q, Long Y, Lin S, Wang S, Wang Z, Li Y, Chen Y, He Q, Chen S, Yao H, Liu Z, Tang Z, Yao Y, Pei D, Liu P, Zhang X, Zhang Z, Cui S, Chen R, Li P*. Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer. J Hematol Oncol. 2019 Feb 18;12(1):18.
  13. Zhao R, Cheng L, Jiang Z, Wei X, Li B, Wu Q, Wang S, Lin S, Long Y, Zhang X, Wu Y, Du X, Pei D, Liu P, Li Y, Cui S, Yao Y*, Li P*. DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells. Oncoimmunology. 2018 Nov 2;8(1):e1509173.
  14. Lin S#, Huang G#, Cheng L#, Li Z, Xiao Y, Deng Q, Jiang Y, Li B, Lin S, Wang S, Wu Q, Yao H, Cao S, Li Y, Liu P, Wei W, Pei D, Yao Y, Wen Z, Zhang X, Wu Y, Zhang Z, Cui S, Sun X, Qian X*, Li P*. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy. MAbs. 2018 Oct 02. 10:8:1301-1311.
  15. Lai Y#, Weng J#, Wei X, Qin L, Lai P, Zhao R, Jiang Z, Li B, Lin S, Wang S, Wu Q, Tang Z, Liu P, Pei D, Yao Y, Du X*, Li P*. Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells. Leukemia. 2018 Mar;32(3):801-808. Epub 2017 Aug 3.
  16. Weng J#, Lai P#, Qin L#, Lai Y, Jiang Z, Luo C, Huang X, Wu S, Shao D, Deng C, Huang L, Lu Z, Zhou M, Zeng L, Chen D, Wang Y, Chen X, Geng S, Robert W, Tang Z, He C, Li P*, Du X*. A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia. J Hematol Oncol. 2018 Feb 20;11(1):25.
  17. Lin S#, Huang G#, Xiao Y, Sun W, Jiang Y, Deng Q, Peng M, Wei X, Ye W, Li B, Lin S, Wang S, Wu Q, Liang Q, Li Y, Zhang X, Wu Y, Liu P, Pei D, Yu F, Wen Z, Yao Y, Wu D*, Li P*. CD215+ Myeloid Cells Respond to Interleukin 15 Stimulation and Promote Tumor Progression. Front Immunol. 2017 Dec 4;8:1713.
  18. Zhang L#, Zhou Y#, Chen K#, Shi P, Li Y, Deng M, Jiang Z, Wang X, Li P*, Xu B*. The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells. Target Oncol. 2017 Oct;12(5):677-687.
  19. Wei X#, Lai Y, Li B, Qin L, Xu Y, Lin S, Wang S, Wu Q, Liang Q, Huang G, Deng Q, Liu P, Wu D, Lai L, Yao Y*, Li P*. CRISPR/Cas9-Mediated Deletion of Foxn1 in NOD/SCID/IL2rg-/- Mice Results in Severe Immunodeficiency. Sci Rep. 2017 Aug 10;7(1):7720.
  20.  Qin L#, Lai Y#, Zhao R, Wei X, Weng J, Lai P, Li B, Lin S, Wang S, Wu Q, Liang Q, Li Y, Zhang X, Wu Y, Liu P, Yao Y, Pei D, Du X, Li P*. Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells. J Hematol Oncol. 2017 Mar 13;10(1):68.
  21. Wei X#, Lai Y#, Li J, Qin L, Xu Y, Zhao R, Li B, Lin S, Wang S, Wu Q, Liang Q, Peng M, Yu F, Li Y, Zhang X, Wu Y, Liu P, Pei D, Yao Y*, Li P*. PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells. Oncoimmunology. 2017 Feb 6;6(3):e1284722.
  22. Jiang Z#, Jiang X#, Chen S, Lai Y, Wei X, Li B, Lin S, Wang S, Wu Q, Liang Q, Liu Q, Peng M, Yu F, Weng J, Du X, Pei D, Liu P, Yao Y, Xue P*, Li P*. Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma. Front Immunol. 2017 Jan 11;7:690. 
  23. Jiang Z#, Deng M#, Wei X, Ye W, Xiao Y, Lin S, Wang S, Li B, Liu X, Zhang G, Lai P, Weng J, Wu D, Chen H, Wei W, Ma Y, Li Y, Liu P, Du X, Pei D, Yao Y, Xu B*, Li P*. Heterogeneity of CD34 and CD38 expression in acute B lymphoblastic leukemia cells is reversible and not hierarchically organized. J Hematol Oncol. 2016 Sep 22;9(1):94.
  24. Sun W, Lai Y, Li H, Nie T, Kuang Y, Tang X, Li K, Dunbar PR, Xu A, Li P*, Wu D*. High level expression and purification of active recombinant human interleukin-15 in Pichia pastoris. J Immunol Methods. 2016 Jan;428:50-7.
  25. Yin Li#, Kai Chen#, Yong Zhou#, Yiren Xiao, Manman Deng, Zhiwu Jiang, Wei Ye, Xiangmeng Wang, Xinru Wei, Jie Li, Jiabao Liang, ZhongxinZheng, Yao Yao, WeiguangWang,Peng Li*,Bing Xu*.A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone DeacetylaseInhibitor. Current Cancer Drug Targets. 2015;15(6):493-503.
  26. Ye W#, Jiang Z#, Li GX, Xiao Y, Lin S, Lai Y, Wang S, Li B, Jia B, Li Y, Huang ZL, Li J, Feng F, Li S, Yao H, Liu Z, Cao S, Xu L, Li Y, Wu D, Zeng L, Zhong M, Liu P, Wen ZS, Xu B, Yao Y, Pei D*, Li P*. Quantitative evaluation of the immunodeficiency of a mouse strain by tumor engraftments. J Hematol Oncol. 2015 May 29;8:59.
  27. Xiao Y#, Jiang Z, Li Y, Ye W, Jia B, Zhang M, Xu Y, Wu D, Lai L, Chen Y, Chang Y, Huang X, Liu H, Qing G, Liu P, Li Y, Xu B, Zhong M, Yao Y, Pei D, Li P*. ANGPTL7 regulates the expansion and repopulation of human hematopoietic stem and progenitor cells. Haematologica. 2015 May;100(5):585-94.
  28. Li W#, Jiang Z#, Li T, Wei X, Zheng Y, Wu D, Yang L, Chen S, Xu B, Zhong M, Jiang J, Hu Y, Su H, Zhang M, Huang X, Geng S, Weng J, Du X, Liu P, Li Y, Liu H, Yao Y*, Li P*. Genome-wide analyses identify KLF4 as an important negative regulator in T-cell acute lymphoblastic leukemia through directly inhibiting T-cell associated genes. Mol Cancer. 2015 Feb 3;14:26.
  29. Xiao Y#, Wei X, Jiang Z, Wang X, Ye W, Liu X, Zhang M, Xu Y, Wu D, Lai L, Yao H, Liu Z, Cao S, Liu P, Xu B, Li Y, Yao Y, Pei D*, Li P*. Loss of Angiopoietin-like 7 diminishes the regeneration capacity of hematopoietic stem and progenitor cells. J Hematol Oncol. 2015 Feb 6;8:7.
  30. Li P#, Burke S, Wang J, Chen X, Ortiz M, Lee SC, Lu D, Campos L, Goulding D, Ng BL, Dougan G, Huntly B, Gottgens B, Jenkins NA, Copeland NG, Colucci F, Liu P. Reprogramming of T cells to natural killer-like cells upon Bcl11b deletion. Science. 2010 Jul 2;329(5987):85-9. Epub 2010 Jun 10.
  31.  Lv J, Li P*. Mesothelin as a biomarker for targeted therapy. Biomark Res. 2019 Aug 23; 7: 18. Review.
  32. Qin L, Zhao R, Li P*. Incorporation of functional elements enhances the antitumor capacity of CAR T cells. Exp Hematol Oncol. 2017 Oct 11;6:28.
  33. Lai Y, Wei X, Lin S, Qin L, Cheng L, Li P*. Current status and perspectives of patient-derived xenograft models in cancer research. J Hematol Oncol. 2017;10(1):106. Published 2017 May 12. Review.
  34.  Zhao R#., Lai Y, Li P*., Kruppel-Like Factor 4: From Physiological Functions to Tumor Therapy. Forum on Immunopathological Diseases and Therapeutics. Volume 7, 2016 Issue 1-2. Review.
  35. Jiang Z#, Wu D, Lin S, Li P*. CD34 and CD38 are prognostic biomarkers for acute B lymphoblastic leukemia. Biomark Res. 2016 Dec 16;4:23. Review.
  36.  Lin S#, Zhao R, Xiao Y, Li P*. Mechanisms determining the fate of hematopoietic stem cells. Stem Cell Investig. 2015 May 15;2:10..2015.05.01. Review.
  37. Li P#, Xiao Y, Liu Z, Liu P*. Using mouse models to study function of transcriptional factors in T cell development. Cell Regen. 2012 Oct 10;1(1):8. Review.

Patents

Peng Li has filed 17 patents, 12 representative patents listed as below:

1.    “A method to establish the immunodeficient mice”, Application number: ZL201310229629.9, Granted;

2.    “A method to evaluate the immunodeficiency of mouse strain, Application number: ZL201510179449.3, Granted;

3.    “Cells, compositions and methods”(Production and Application of ITNKs), Application number: PCT/GB2010/051158, Granted; (PCT)

4.    “A method to induce BCL11B protein degradation”, Application number: ZL201310199598.7, Granted;

5.    “The application of mice fetal liver cell line PL08 in the preservation of mature red blood cells”, Application number: ZL201210315986.2, Granted;

6.    “The application of mice fetal liver cell line PL08 in the culture and proliferation of mature red blood cells”, Application number: ZL201210316587.8, Granted;

7.    “A culture medium to stimulate cord blood hematopoietic stem cells proliferation”, Application number: ZL201310349485.0, Granted;

8.    “A culture method to induce human hematopoietic stem cells differentiation”, Application number: ZL201310349474.2, Granted;

9.    “The application of mice fetal liver cell line PL08 in the preservation of mature red blood cells”, Application number: ZL201210316523.8, Granted;

10.   “a method to culture primary acute B lymphoblastic leukemia cells in vitro”, Application number:ZL201410778012.7, Granted;

11.   “A cell culture medium for human primary cells and the use thereof”, Application number: PCT/CN2015/079846, Acceptance stage; (PCT)

12.   “A method to detect the inhibition of anti-CD19 chimeric antigen receptor T cells to leukemia cells”, Application number: ZL201510223496.3, Granted;

Conferences Report

2009, Cancer Model and Mechanism, the annual conference of Cambridge University

2010, Gene Expression & Signaling in the Immune System, Cold Spring Harbor Laboratory

2010, the 3rd Guangzhou International Conference on Stem Cell and Regenerative Medicine

2013, the Chinese Experimental Hematology Annual Conference

2014, New aspect of molecular pathogenesis in lymphocytic malignancies, 1st Chinese-German Hematological Symposium

2015, New Zealand Branch Meeting, the Australasian Society for Immunology

2016, Guangdong Provincial Society of Immunology Annual Meeting

2016, the 11th Southern Blood Forum and the new drug era multiple myeloma patients genetics basis and method selection class

2016, the 5th Guangzhou Hematology Summit Forum

2016, the first academic conference of the Chinese Research Hospitals Cell Research and Therapy Committee & the 7th Asian Cell Therapy Annual Meeting

2016, Seminar on New Progress in Detection and Clearance of Circulating Tumor Cells (CTC)

2017, the Academic Symposium of the Blood Disease Branch of the Guangdong Medical Association-the inaugural meeting of the Youth Committee

2017, the 3rd Next Generation CAR&TCR-T Seminar Next-generation CAR & TCR-T Seminar

2018, the 4th Shanghai International Lymphoma Summit Forum

2018, the China-New GIBH-MWC scientists exchange meeting

2018, CSCO Anti-Leukemia Alliance Tour-Guangzhou Station/Guangdong Medical Association Hematology Society Leukemia Group Annual Meeting/Leukemia Diagnosis and Immunotherapy New Progress Class

2019, Invited report on the China-UK Stem Cell Conference

Students

Graduated students:

Wei Li  Doctoral degree  071010-Biochemistry and Molecular Biology

Tianzhong Li  Master degree 071010-Biochemistry and Molecular Biology 

Zhiwu Jiang  Doctoral degree 071009-Cell Biology

Xunxin Lai  Doctoral degree  071009-Cell Biology  

Yiren Xiao  Doctoral degree  071009-Cell Biology  

Shouheng Lin  Doctoral degree  071009-Cell Biology  

Ruocong Zhao  Doctoral degree  071009-Cell Biology  

Jiang Lv  Master degree  085238-Bioengineering

Le Qin  Doctoral degree  100102-Immunology 

Rui Liao  Doctoral degree  100102-Immunology

Jingxuan Shi  Doctoral degree  100102-Immunology

Diwei Zheng  Doctoral degree  100102-Immunology

Yuanbin Cui  Doctoral degree   100102-Immunology

Shanglin Li   Doctoral degree   100102-Immunology

 

Students under study:

Jiang Lv  Doctoral degree  100102-Immunology

Zhiping Wu  Doctoral degree  100102-Immunology  

Yongfang Zheng  Doctoral degree  100102-Immunology  

Yunlin Huang  Doctoral degree  100102-Immunology  

Linfu Zhou  Doctoral degree  100102-Immunology  

Yao Li  Doctoral degree  100102-Immunology  

Dongdong Peng  Master degree  100102-Immunology

Meihui Che  Master degree  071008-Developmental  Biology